A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan

A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan

BackgroundAnti-programmed death-1 (PD-1) antibodies are the mainstay for the treatment of unresectable or high-risk melanoma. However, real-world data on the safety profile of their extended-interval doses (EDs) are limited, particularly in Asian patients with melanoma.Materials and methodsIn this s...

Full description

Bibliographic Details
Main Authors: Takamichi Ito, Yumiko Kaku-Ito, Fumitaka Ohno, Takeshi Nakahara
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Medicine
Subjects:
acral melanoma
Asian population
nivolumab
PD-1
pembrolizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1293397/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1293397/full

Similar Items